A treatment algorithm for neuropathic pain: An update

Consultant Pharmacist

Volumn 24, Issue 12, 2009, Pages 885-902

  Namaka, Michael ^a,b   Leong, Christine ^a   Grossberndt, Amy ^a   Klowak, Meghann ^c   Turcotte, Dana ^a   Esfahani, Farid ^b   Gomori, Andrew ^b   Intrater, Howard ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

Author keywords

Clinical symptoms; Dorsal horn neurons; Neuronal hyperexcitability; Neuropathic pain; Treatment algorithm

Indexed keywords

ACETYLSALICYLIC ACID; ALFENTANIL; AMFEBUTAMONE; AMITRIPTYLINE; CAFFEINE; CANNABIS; CARBAMAZEPINE; CELECOXIB; CODEINE; DESIPRAMINE; DULOXETINE; FLUOXETINE; GABAPENTIN; IBUPROFEN; LAMOTRIGINE; METHADONE; MORPHINE; NABILONE; NAPROXEN; NORTRIPTYLINE; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PAROXETINE; PHENYTOIN; PREGABALIN; SERTRALINE; TOPIRAMATE; TRAMACET; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; ZYTRAM;

ADJUVANT THERAPY; AGITATION; ANALGESIA; ANTICONVULSANT THERAPY; ATAXIA; BLOOD PRESSURE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC PAIN; CLINICAL TRIAL; COCHRANE LIBRARY; COMA; CONFUSION; CONSTIPATION; CONTROLLED DRUG RELEASE; DATA ANALYSIS; DATA EXTRACTION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EDEMA; EUPHORIA; EVIDENCE BASED MEDICINE; FATIGUE; FIBROMYALGIA; HALLUCINATION; HEART FAILURE; HUMAN; HYPERTHERMIA; INFORMATION RETRIEVAL; MAJOR DEPRESSION; MEDLINE; MOUTH ULCER; NAUSEA; NEUROPATHIC PAIN; OFF LABEL DRUG USE; PANIC; PARANOIA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PREMENSTRUAL SYNDROME; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; SWEATING; TACHYCARDIA; TASTE DISORDER; TREMOR; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

ALGORITHMS; ANALGESICS; GAMMA-AMINOBUTYRIC ACID; HUMANS; NEURALGIA; PAIN MEASUREMENT; PAROXETINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES;

EID: 73949106283     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2009.885     Document Type: Review

References (90)

1. Namaka M, Gramlich CR, Ruhlen D et al. A treatment algorithm for neuropathic pain. Clin Ther 2004;26:951-79.
2. Ignatowski TA, Covey WC, Knight PR et al. Brain-derived TNF-alpha mediates neuropathic pain. Brain Res 1999;841:70-7.
3. Winkelstein BA, Rutkowski MD, Sweitzer SM et al. Nerve injury proximal or distal to the DRG induces similar spinal glial activation and selective cytokine expression but differential behavioral responses to pharmacologic treatment. J Comp Neurol 2001;439:127-39.
4. Koltzenburg M, Scadding J. Neuropathic pain. Curr Opin Neurol 2001;14:641-7.
5. Bouhassira D, Attal N, Alchaar H et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29-36.
6. Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain 1983;16:87-101.
7. FDA. Center for Drug Evaluation and Research. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.DrugDetails. Accessed August 4, 2008.
8. Health Canada Drugs and Health Products. Notice of compliance with conditions. Available at http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/ conditions/lyrica-dhcpl-lapds-103320-eng.php. Accessed August 4, 2008.
9. Wesche D, Bockbrader H. A pharmacokinetic comparison of pregabalin and gabapentin. Available at http://www.ampainsoc.org/abstract/2005/data/684/index. html. Accessed June 9, 2009.
10. Van Meeteren ME, Teunissen CE, Dijkstra CD et al. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur J Clin Nutr 2005;59:1347-61.
11. Finnerup NB, Otto M, McQuay HJ et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305.
12. Siddall PJ, Cousins MJ, Otte A et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006;67:1792-800.
13. Page RL 2nd, Cantu M, Lindenfeld J et al. Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. J Cardiovasc Med (Hagerstown) 2008;9:922-5.
14. Murphy N, Mockler M, Ryder M et al. Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain. J Card Fail 2007;13:227-9.
15. Freynhagen R, Strojek K, Griesing T et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-63.
16. Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends in Pharmacological Sciences 2004;25:613-7.
17. Golden RN, Nemeroff CB, McSorley P et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002;63:577-84.
18. Cohen LS, Soares CN, Yonkers KA et al. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med 2004;66:707-13.
19. Patkar AA, Masand PS, Krulewicz S et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med 2007;120:448-54.
20. Dunner DL, Lipschitz A, Pitts CD et al. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials. Clin Ther 2005;27:1901-11.
21. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36.
22. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000;403:17-25.
23. Won R, Lee BH, Park S et al. Role of different peripheral components in the expression of neuropathic pain syndrome. Yonsei Med J 2000;41:354-61.
24. Ignatowski TA, Covey WC, Knight PR et al. Brain-derived TNF-alpha mediates neuropathic pain. Brain Res 1999;841:70-7.
25. Sindrup SH, Otto M, Finnerup NB et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005;96:399-409.
26. LexiCompONLINE. Paroxetine monograph. Updated June 19, 2009. Available at http://online.lexi.com.proxy1.lib.umanitoba.ca/crlsql/servlet/crlonline. Accessed June 20, 2009.
27. Collins SL, Moore RA, McQuay HJ et al. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manag 2000;20:449-58.
28. Watson CP, Watt-Watson JH. Treatment of neuropathic pain: focus on antidepressants, opioids and gabapentin. Pain Res Manag 1999;4:168-78.
29. Davis MP. What is new in neuropathic pain? Support Care Cancer 2007;15:363-72.
30. Raskin J, Pritchett YL, Wang F et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56.
31. Goldstein DJ, Lu Y, Detke MJ et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-18.
32. Gidal BE. New and emerging treatment options for neuropathic pain. Am J Manag Care 2006;12 9 Suppl:269-78.
33. Bauer M, Moller HJ, Schneider E. Duloxetine: a new selective and dual-acting antidepressant. Exp Opin Pharmacother 2006;7:421-7.
34. Is there a place for duloxetine? Drug Ther Bull 2007;45:29-32.
35. Westanmo AD, Gayken J, Haight R. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Am J Health Syst Pharm 2005;62:2481-90.
36. Kajdasz DK, Iyengar S, Desaiah D et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007;29:2536-46.
37. Derby MA, Zhang L, Chappell JC et al. The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol 2007;49:384-93.
38. MacPherson RD. The pharmacological basis of contemporary pain management. Pharmacol Ther 2000;88:163-85.
39. Garcia J, Altman RD. Chronic pain states: pathophysiology and medical therapy. Semin Arthritis Rheum 1997;27:1-16.
40. Nagaoka E, Minami K, Shiga Y et al. Tramadol has no effect on cortical renal blood flow - despite increased serum catecholamine levels - in anesthetized rats: implications for analgesia in renal insufficiency. Anesth Analg 2002;94:619-25; table of contents.
41. Hollingshead J, Duhmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2006;3:CD003726.
42. Harati Y, Gooch C, Swenson M et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842-6.
43. Sindrup SH, Madsen C, Brosen K et al. The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clin Pharmacol Ther 1999;66:636-41.
44. Enggaard TP, Poulsen L, Arendt-Nielson L et al. The analgesic effect of tramadol after intravenous injector in healthy volunteers in relations to CYP2D6. Anesth Analg 2006;102:146-50.
45. Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993;46:313-40.
46. Nicholson B, Verma S. Comorbidities in chronic neuropathic pain. Pain Med 2004;5 Suppl 1:9-27.
47. Wittchen HU, Kessler RC, Beesdo et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002;63 Suppl 8:24-34.
48. Laugesen S, Enggaard TP, Pedersen RS et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the heteroselective O-demethylation and reduces the hypoanalgesic effect of tramadol. Clin Pharmacol Ther 2005;77:312-23.
49. Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther 2007;29:2477-97.
50. Forde G. Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles. J Fam Pract 2007;56 2 Suppl Pain:3-12.
51. Ruoff G. Slowing the initial titration rate of tramadol improves tolerability. Pharmacotherapy 1999;19:88-93.
52. Petrone D, Kamin M, Olson W. Slowing the titration rate of tramadol HCl reduces the incidence of discontinuation due to nausea and/or vomiting: a double-blind randomized trial. J Clin Pharm Ther 1999;24:115-23.
53. Schnitzer T. The new analgesic combination tramadol/acetaminophen. Eur J Anaesthesiol Suppl 2003;28:13-7.
54. Freeman R, Raskin P, Hewitt DJ et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin 2007;23:147-61.
55. Tallarida RJ, Raffa RB. Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram. Life Sci 1996;58:23-8.
56. Health Canada Drug and Health Products. Notice of decision for Tramacet. Available at http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1-decision/ drug-med/nd-ad-2005-tramacet-095167-eng.php. Accessed August 4, 2008.
57. Bennett RM, Kamin M, Karim R et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003;114:537-45.
58. Iversen L. Cannabis and the brain. Brain 2003;126:1252-70.
59. Matsuda LA, Lolait SJ, Brownstein MJ et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
60. Bonz A, Laser M, Kullmer S et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 2003;41:657-64.
61. Liu J, Gao B, Mirshahi F et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000;346:835-40.
62. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
63. Jhaveri MD, Elmes SJ, Richardson D et al. Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats. Eur J Neurosci 2008;27:1722-30.
64. Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barcelona) 2006;42:495-503.
65. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Exp Opin Pharmacother 2006;7:607-15.
66. Smith PF. GW-1000. GW Pharmaceuticals. Curr Opin Invest Drugs 2004;5:748-54.
67. Cannabis-based medicines - GW Pharmaceuticals: high CBD, high THC, medicinal cannabis - GW Pharmaceuticals, THC: CBD. Drugs RD 2003;4:306-9.
68. Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berlin) 1991;104:260-4.
69. Bisogno T, Hanus L, De Petrocellis L et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-52.
70. Offertaler L, Mo FM, Batkai S et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 2003;63:699-705.
71. Petitet F, Jeantaud B, Reibaud M et al. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9- tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 1998;63:1-6.
72. Mechoulam R, Hanus L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 2002;121:35-43.
73. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001;48:859-67.
74. McPartland J, Russo E. Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther 2001;1:103-32.
75. Petro DJ. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 1980;21:81, 85.
76. D'Arcy Y. New pain management options: drugs. Nursing 2007; 37:18-9.
77. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004;112:299-306.
78. Perras C. Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol 2005:1-4.
79. Scully C. Cannabis; adverse effects from an oromucosal spray. Br Dent J 2007;203:12; discussion 336-7.
80. Clark AJ, Lynch ME, Ware M et al. Guidelines for the use of cannabinoid compounds in chronic pain. Pain Res Manag 2005;10 Suppl A:44-6.
81. McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 2005;10:15-22.
82. Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med 2006;7:25-9.
83. Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 2001;56:1059-68.
84. Hamann W, di Vadi PP. Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 1999;353:560.
85. Redmond WJ, Goffaux P, Potvin S et al. Analgesic and antihyperanalgesic effects of nabilone on experimental heat pain. Curr Med Res Opin 2008;24;1017-24.
86. Tarride JE, Gordon A, Vera-Llonch M et al. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther 2006;28:1922-34.
87. Hans GH, Robert DN, Van Maldeghem KN. Treatment of acute severe central neuropathic pain syndrome by topical application of lidocaine 5% patch: a case report. Spinal Cord 2008;46:311-3.
88. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2007 Apr 18:CD004846.
89. American Geriatrics Society Panel. Pharmacologic management of persistent pain in older persons. 2009. Available at http://www.americangeriatrics.org/ education/pharm-management.shtml. Accessed June 20, 2009.
90. Ilse WK. Neuropathic pain: mechanisms, diagnosis and treatment. Can J Continuing Med Education 2002;14:99-108.